|
[이데일리 강경래 기자] SK Bioscience has begun clinical phase 1 administration of the second Corona 19 vaccine candidate’GBP510′.
According to the industry on the 31st, a team of professors at the University of Washington, University of Washington, who is jointly developing the vaccine candidate, said, “The corona19 vaccine candidate was administered to humans.” Will”.
GBP510 is a recombinant vaccine that uses gene recombination technology to create a corona 19 surface antigen protein. When the vaccine surface antigen protein stimulates immune cells, neutralizing antibodies are formed, which induces an immune response. When Corona 19 invades, antibodies remove the virus.
GBP510 is a candidate for a COVID-19 vaccine that is being developed jointly with the University of Washington Antigen Design Research Institute by SK Bioscience in May of last year. Earlier, in November of last year, SK Bioscience received approval for a clinical trial for another COVID-19 vaccine candidate’NBP2001′, not GBP510.
– .
